Surrozen (SRZN) Retained Earnings (2020 - 2026)
Surrozen (SRZN) posted quarterly Retained Earnings of -$654.8 million for Q1 2026, down 305.98% year-over-year from $317.9 million in Q1 2025, and down 24.18% quarter-over-quarter from -$527.3 million in Q4 2025.
Analysis
Surrozen (SRZN) Retained Earnings (2020 - 2026) Analysis & Trends
Surrozen's Retained Earnings history runs 7 years deep, the most recent figure standing at -$654.8 million for Q1 2026.
- In Q1 2026, Retained Earnings fell 305.98% year-over-year to -$654.8 million; the TTM figure through Mar 2026 stood at -$654.8 million (down 305.98% YoY), while the FY2025 annual figure was -$527.3 million, down 299.82% from the prior year.
- Retained Earnings for Q1 2026 stood at -$654.8 million, down from -$527.3 million in the prior quarter.
- The five-year high for Retained Earnings was $317.9 million in Q1 2025, with the low at -$654.8 million in Q1 2026.
- The 5-year median for Retained Earnings is -$177.9 million (2022), against an average of -$92.8 million.
- The sharpest annual moves came in 2022 and 2023: Retained Earnings plunged 2670.01% in 2022, then surged 256.45% in 2023.
- Surrozen's Retained Earnings stood at $254.9 million in 2022, then tumbled by 186.98% to -$221.7 million in 2023, then jumped by 219.03% to $263.9 million in 2024, then plunged by 299.82% to -$527.3 million in 2025, then decreased by 24.18% to -$654.8 million in 2026.
- Business Quant data shows SRZN's Retained Earnings at -$654.8 million in Q1 2026, -$527.3 million in Q4 2025, and -$344.1 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.10 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -4.00 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.05 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -6.33 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 4.38 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Surrozen | 263.35 Mn | 263.35 Mn | - | -604.61 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -604.61 Mn |
| Mar 31, 2026 | -654.80 Mn |
| Dec 31, 2025 | -527.29 Mn |
| Sep 30, 2025 | -344.13 Mn |
| Jun 30, 2025 | 319.60 Mn |
| Mar 31, 2025 | 317.90 Mn |
| Dec 31, 2024 | -285.26 Mn |
| Sep 30, 2024 | 262.89 Mn |
| Jun 30, 2024 | 261.85 Mn |
| Mar 31, 2024 | 260.66 Mn |
| Dec 31, 2023 | 259.63 Mn |
| Sep 30, 2023 | 258.31 Mn |
| Jun 30, 2023 | 257.39 Mn |
| Mar 31, 2023 | 256.03 Mn |
| Dec 31, 2022 | 254.90 Mn |
| Sep 30, 2022 | 255.79 Mn |
| Jun 30, 2022 | 254.69 Mn |
| Mar 31, 2022 | 253.68 Mn |
| Dec 31, 2021 | 252.46 Mn |
| Sep 30, 2021 | 251.44 Mn |